Compare BYD & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYD | DYN |
|---|---|---|
| Founded | 1973 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.8B |
| IPO Year | 1996 | 2020 |
| Metric | BYD | DYN |
|---|---|---|
| Price | $81.26 | $26.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $90.82 | $37.00 |
| AVG Volume (30 Days) | 790.2K | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 264.46 | N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $2,626,730,000.00 | N/A |
| Revenue This Year | $1.71 | N/A |
| Revenue Next Year | $2.74 | N/A |
| P/E Ratio | $26.00 | ★ N/A |
| Revenue Growth | ★ 9.41 | N/A |
| 52 Week Low | $76.33 | $11.92 |
| 52 Week High | $91.41 | $27.31 |
| Indicator | BYD | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 58.43 |
| Support Level | $79.66 | $16.45 |
| Resistance Level | $87.08 | $26.96 |
| Average True Range (ATR) | 1.34 | 0.94 |
| MACD | -0.22 | -0.16 |
| Stochastic Oscillator | 19.90 | 55.43 |
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. The Midwest and South hold the key number of entertainment properties and generate the majority of the company's revenue.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.